B
Bull
Bull · 25%SCNI
$2.77
Precio del escenario
$2.510
-0.159 (-6.34%)Al cierre
Loading chart…
- High
- 2.980
- Open
- 2.700
- VWAP
- 2.61
- Vol
- 37.50K
- Mkt Cap
- 1.66M
- Low
- 2.330
- Amount
- 97.75K
- EV/EBITDA, TTM
- 0.00
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
AI analysis of Scinai Immunotherapeutics Ltd (SCNI)
holdScinai Immunotherapeutics Ltd is currently not a strong buy due to its recent performance and financial instability. The stock is trading at $2.51, down 22.05% over the last five days and 65.59% year-to-date. Although the company reported a net income of $3.6 million in Q1 2026, this was primarily due to a non-cash gain, and the gross margin remains negative at -228.63%. The RSI is at 36.187, indicating potential oversold conditions, but the overall trend is bearish. The main risk is the Nasdaq notice regarding minimum bid price requirements, which could further impact the stock negatively.
Métricas de valoración
The current forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI) is 0.00, compared to its 5-year average forward P/E of -4.95.
Alphio AI Price Scenarios for SCNI
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.508-24PRnewswireScinai Immunotherapeutics Provides Corporate Update and Financial Results
9.508-24NewsfilterScinai Immunotherapeutics Reports Mid-Year Financial Results for 2026
5.008-10PRnewswireScinai Appoints New Head of Supply Chain
- 5.008-10Newsfilter
Scinai Appoints New Head of Supply Chain to Enhance CDMO Operations
9.506-11seekingalphaScinai Immunotherapeutics Reports Strong Q1 Earnings with Significant Net Income Growth
SCNI FAQ — answered by Alphio AI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Scinai Immunotherapeutics Ltd is currently not a strong buy due to its recent performance and financial instability. The stock is trading at $2.51, down 22.05% over the last five days and 65.59% year-to-date. Although the company reported a net income of $3.6 million in Q1 2026, this was primarily due to a non-cash gain, and the gross margin remains negative at -228.63%. The RSI is at 36.187, indicating potential oversold conditions, but the overall trend is bearish. The main risk is the Nasdaq notice regarding minimum bid price requirements, which could further impact the stock negatively.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.